Welcome to Signed Sealed Weekend, our inside track into the Swiss legal scene. This week we anticipate our recap to Thursday, as we’re approaching the Easter weekend and we start-off with our banking &
Tags :Loyens & Loeff
Kellerhals Carrard advised the selling part in the sale of all the shares in Senn Chemicals to Granules India. Moreover, Loyens & Loeff represented Granules India throughout the operation. The parties signed the deal in
Loyens & Loeff advised Swedish listed Alfa Laval as Swiss counsel on a binding put-option agreement to acquire the Fives Cryogenics business unit, part of the French Fives Group, for a total fixed purchase price
Loyens & Loeff hired Daniel Dedeyan (pictured) as a new partner. The addition is set to bolster the firm’s Banking & Finance practice. Dedeyan moves to Loyens & Loeff from a counsel position at
Loyens & Loeff advised Swiss data management specialist Redslim Group and its founders on the sale of a majority stake to Astorg Private Equity. Loyens & Loeff’s Swiss team acted as tax and
Loyens & Loeff advised alternative investment firm H.I.G. Capital in connection with its investment in German IT company Timetoact Group. The context Headquartered in Cologne, Timetoact specialises in cloud platforms and digital
American payment processing company Shift4 agreed to acquire specialty payments platform Global Blue. Loyens & Loeff has been advising the buyer, while NKF represented the selling part. The deal Headquartered in Pennsylvania, Shift4 provides more
Nicolas Wehrli has joined Loyens & Loeff ‘s Zurich office as a partner in the corporate and M&A practice group. Wehrli has extensive experience representing clients in complex M&A, private equity
Loyens & Loeff has appointed Christine Hohl (pictured) as local partner effective 1 May. Hohl advises clients in financing transactions including acquisition financings, asset financings, real estate financings, debt issuances and securitisations. Her clients include banks,
Investindustrial, a leading European group in the field of private equity, has signed an agreement through one of its investment vehicles for the entry of QuattroR into the capital of Medical Technology and Devices Group.
